Patents by Inventor Harold Kleanthous

Harold Kleanthous has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of generating broadly protective vaccine compositions comprising hemagglutinin
    Patent number: 11576964
    Abstract: The present disclosure relates to a cluster-based consensus approach for generating recombinant hemagglutinin (HA) polypeptides. The disclosure further relates to influenza vaccine compositions comprising the recombinant HA polypeptides.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: February 14, 2023
    Assignee: Sanofi Pasteur Inc.
    Inventors: Tod Strugnell, Eliud Oloo, Raymond Oomen, Thorsten Vogel, Harold Kleanthous
  • ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINS AND METHODS OF USING THE SAME
    Publication number: 20220089700
    Abstract: Monoclonal antibodies, or antigen-binding fragments thereof, that bind to Clostridium difficile (C. difficile) toxin A or toxin B and methods of using the same to detect or treat C. difficile infections and/or C. difficile-associated disease.
    Type: Application
    Filed: November 30, 2021
    Publication date: March 24, 2022
    Inventors: Stephen F. Anderson, Natalie Anosova, Nicola Beltraminelli, Pierre Garrone, Harold Kleanthous, Majid Mehtali, Jianxin Zhang
  • Antibodies against toxins and methods of using the same
    Patent number: 11220537
    Abstract: Monoclonal antibodies, or antigen-binding fragments thereof, that bind to Clostridium difficile (C. difficile) toxin A or toxin B and methods of using the same to detect or treat C. difficile infections and/or C. difficile-associated disease.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: January 11, 2022
    Assignee: SANOFI PASTEUR BIOLOGICS, LLC
    Inventors: Stephen F. Anderson, Natalie Anosova, Nicola Beltraminelli, Pierre Garrone, Harold Kleanthous, Jianxin Zhang, Majid Mehtali
  • METHODS OF GENERATING BROADLY PROTECTIVE VACCINE COMPOSITIONS COMPRISING HEMAGGLUTININ
    Publication number: 20210128715
    Abstract: The present disclosure relates to a cluster-based consensus approach for generating recombinant hemagglutinin (HA) polypeptides. The disclosure further relates to influenza vaccine compositions comprising the recombinant HA polypeptides.
    Type: Application
    Filed: March 27, 2019
    Publication date: May 6, 2021
    Applicant: Sanofi Pasteur Inc.
    Inventors: Tod STRUGNELL, Eliud OLOO, Raymond OOMEN, Thorsten VOGEL, Harold KLEANTHOUS
  • Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza
    Patent number: 10925957
    Abstract: Co-administration (for example, immunogenic cocktail compositions and/or prime boost regimens) of computationally optimized H1N1 influenza hemagglutinin (HA) polypeptides is provided. Coadministration of the optimized H1N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (for example, a broad reactive immune response) to diverse and multiple H1N1 influenza virus strains, including both seasonal and pandemic strains.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: February 23, 2021
    Assignees: OREGON HEALTH & SCIENCE UNIVERSITY, SANOFI PASTEUR, INC.
    Inventors: Ted Milburn Ross, Tim Alefantis, Donald Martin Carter, Jr., Christopher Austin Darby, Harold Kleanthous
  • Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian H5N1 influenza
    Patent number: 10548965
    Abstract: The present invention provides co-administration (e.g., immunogenic cocktail and/or prime-boost regimens) of computationally optimized H5N1 influenza hemagglutinin (HA) polypeptides that. Co-administration of the optimized H5N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (e.g., a broad reactive immune response) to multiple H5N1 influenza virus clades and strains.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 4, 2020
    Assignees: Oregon Health & Science University, Sanofi Pasteur, Inc.
    Inventors: Ted Milburn Ross, Tim Alefantis, Donald Martin Carter, Christopher Austin Darby, Harold Kleanthous
  • SYNERGISTIC CO-ADMINISTRATION OF COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGENS FOR H1N1 INFLUENZA
    Publication number: 20190175721
    Abstract: The present invention provides co-administration (for example, immunogenic cocktail compositions and/or prime-boost regimens) of computationally optimized H1N1 influenza hemagglutinin (HA) polypeptides. Co-administration of the optimized H1N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (e.g., a broad reactive immune response) to diverse and multiple H1N1 influenza virus strains, including both seasonal and pandemic strains.
    Type: Application
    Filed: January 25, 2019
    Publication date: June 13, 2019
    Inventors: Ted Milburn Ross, Tim Alefantis, Donald Martin Carter, JR., Christopher Austin Darby, Harold Kleanthous
  • ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINS AND METHODS OF USING THE SAME
    Publication number: 20190153078
    Abstract: Monoclonal antibodies, or antigen-binding fragments thereof, that bind to Clostridium difficile (C. difficile) toxin A or toxin B and methods of using the same to detect or treat C. difficile infections and/or C. difficile-associated disease.
    Type: Application
    Filed: November 29, 2018
    Publication date: May 23, 2019
    Inventors: Stephen F. Anderson, Natalie Anosova, Nicola Beltraminelli, Pierre Garrone, Harold Kleanthous, Jianxin Zhang, Majid Mehtali
  • SYNERGISTIC CO-ADMINISTRATION OF COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGENS FOR HUMAN AND AVIAN H5N1 INFLUENZA
    Publication number: 20190111126
    Abstract: The present invention provides co-administration (e.g., immunogenic cocktail and/or prime-boost regimens) of computationally optimized H5N1 influenza hemagglutinin (HA) polypeptides that. Co-administration of the optimized H5N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (e.g., a broad reactive immune response) to multiple H5N1 influenza virus clades and strains.
    Type: Application
    Filed: December 18, 2015
    Publication date: April 18, 2019
    Inventors: Ted Milburn Ross, Tim Alefantis, Donald Martin Carter, Christopher Austin Darby, Harold Kleanthous
  • Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza
    Patent number: 10220086
    Abstract: The present invention provides co-administration (for example, immunogenic cocktail compositions and/or prime-boost regimens) of computationally optimized H1N1 influenza hemagglutinin (HA) polypeptides. Co-administration of the optimized H1N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (e.g., a broad reactive immune response) to diverse and multiple H1N1 influenza virus strains, including both seasonal and pandemic strains.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: March 5, 2019
    Assignees: OREGON HEALTH & SCIENCE UNIVERSITY, SANOFI PASTEUR, INC.
    Inventors: Ted Milburn Ross, Tim Alefantis, Donald Martin Carter, Christopher Austin Darby, Harold Kleanthous
  • Antibodies against toxins and methods of using the same
    Patent number: 10160797
    Abstract: Monoclonal antibodies or antigen-binding fragments thereof, that bind to Clostridium difficile (C. difficile ) toxin A or toxin B and methods of using the same to detect or treat C. difficile infections and/or C. difficile -associated disease. C. difficile is a gram positive, anaerobic bacterium that causes gastrointestinal disease in humans. The bacteria are transmitted through feces and spread to food and other surfaces when people who are infected do not thoroughly wash their hands.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 25, 2018
    Assignee: SANOFI PASTEUR BIOLOGICS, LLC
    Inventors: Stephen F. Anderson, Natalie Anosova, Nicola Beltraminelli, Pierre Garrone, Harold Kleanthous, Jianxin Zhang, Majid Mehtali
  • SYNERGISTIC CO-ADMINISTRATION OF COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGENS FOR H1N1 INFLUENZA
    Publication number: 20170368164
    Abstract: The present invention provides co-administration (for example, immunogenic cocktail compositions and/or prime-boost regimens) of computationally optimized H1N1 influenza hemagglutinin (HA) polypeptides. Co-administration of the optimized H1N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (e.g., a broad reactive immune response) to diverse and multiple H1N1 influenza virus strains, including both seasonal and pandemic strains.
    Type: Application
    Filed: December 18, 2015
    Publication date: December 28, 2017
    Inventors: Ted Milburn Ross, Tim Alefantis, Donald Martin Carter, Christopher Austin Darby, Harold Kleanthous
  • Neutralizing immunogen (NimIV) of rhinovirus and its uses for vaccine applications
    Patent number: 9381237
    Abstract: The invention relates to methods and compositions for preventing or treating human rhinovirus infection.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: July 5, 2016
    Assignee: Sanofi Pasteur Biologics, LLC
    Inventors: Kirill Kalnin, Yanhua Yan, Harold Kleanthous
  • ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINS AND METHODS OF USING THE SAME
    Publication number: 20160068591
    Abstract: Monoclonal antibodies or antigen-binding fragments thereof that bind to Clostridium difficile (C. difficile) toxin A or toxin B and methods of using the same to detect or treat C. difficile infections and/or C. difficile-associated disease. C. difficile is a gram positive, anaerobic bacterium that causes gastrointestinal disease in humans. The bacteria are transmitted through feces and spread to food and other surfaces when people who are infected do not thoroughly wash their hands.
    Type: Application
    Filed: March 14, 2014
    Publication date: March 10, 2016
    Applicant: Sanofi Pasteur Biologics, LLC
    Inventors: Stephen F. ANDERSON, Natalie ANOSOVA, Nicola BELTRAMINELLI, Pierre GARRONE, Harold KLEANTHOUS, Jianxin ZHANG, Majid MEHTALI
  • Recombinant bicistronic flavivirus vectors
    Patent number: 9228203
    Abstract: This invention relates to bicistronic flavivirus vectors, methods of using such vectors in the prevention and treatment of disease, and methods of making such vectors.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: January 5, 2016
    Assignee: Sanofi Pasteur Biologics, LLC
    Inventors: Simon Delagrave, Nathan Brown, Harold Kleanthous, Farshad Guirakhoo, Alexander A. Rumyantsev
  • Replication-defective flavivirus vaccines and vaccine vectors
    Patent number: 9217158
    Abstract: This invention provides replication-defective flavivirus vaccines and vaccine vectors, and corresponding compositions and methods.
    Type: Grant
    Filed: October 2, 2012
    Date of Patent: December 22, 2015
    Assignee: Sanofi Pasteur Biologics, LLC
    Inventors: Konstantin V. Pugachev, Maryann Giel-Moloney, Harold Kleanthous, Mark Parrington, Linong Zhang
  • Replication-defective flavivirus vaccines and vaccine vectors
    Patent number: 8815564
    Abstract: This invention provides replication-defective flavivirus vaccines and vaccine vectors, and corresponding compositions and methods.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: August 26, 2014
    Assignee: Sanofi Pasteur Biologics, LLC
    Inventors: Konstantin V. Pugachev, Alexander A. Rumyantsev, Maryann Giel-Moloney, Harold Kleanthous
  • NOVEL NEUTRALIZING IMMUNOGEN (NIMIV) OF RHINOVIRUS AND ITS USES FOR VACCINE APPLICATIONS
    Publication number: 20140161833
    Abstract: The invention relates to methods and compositions for preventing or treating human rhinovirus infection.
    Type: Application
    Filed: February 18, 2014
    Publication date: June 12, 2014
    Applicant: Sanofi Pasteur Biologics, LLC
    Inventors: Kirill KALNIN, Yanhua Yan, Harold Kleanthous
  • Neutralizing immunogen (NimIV) of rhinovirus and its use for vaccine applications
    Patent number: 8652486
    Abstract: The invention relates to methods and compositions for preventing or treating human rhinovirus infection.
    Type: Grant
    Filed: October 1, 2007
    Date of Patent: February 18, 2014
    Assignee: Sanofi Pasteur Biologics, LLC
    Inventors: Kirill Kalnin, Yanhua Yan, Harold Kleanthous
  • RECOMBINANT BICISTRONIC FLAVIVIRUS VECTORS
    Publication number: 20130295134
    Abstract: This invention relates to bicistronic flavivirus vectors, methods of using such vectors in the prevention and treatment of disease, and methods of making such vectors.
    Type: Application
    Filed: July 15, 2013
    Publication date: November 7, 2013
    Inventors: Simon DELAGRAVE, Nathan Brown, Harold Kleanthous, Farshad Guirakhoo, Alexander A. Rumyantsev